4.4.2025 10:05:55 CEST | Demant A/S |
Antal stemmerettigheder og kapital
Selskabsmeddelelse nr. 2025-06
4. april 2025
Gennemførelse af kapitalnedsættelse i Demant A/S
Som oplyst i selskabsmeddelelse nr. 2025-04 blev det på Demant A/S’ ordinære generalforsamling den 6. marts 2025 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 1.459.025,80 fordelt på 7.295.129 stk. aktier a DKK 0,20 svarende til selskabets beholdning af egne aktier pr. 4. februar 2025 fraregnet aktier til dækning af ledende medarbejderes og direktionens aktiebaserede fastholdelsesprogram.
Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 6. marts 2025. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er derfor anmeldt endeligt til Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Demant A/S nominelt DKK 42.758.932,60.
I henhold til § 32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til:
Aktiekapital (nominelt): DKK 42.758.932,60
Antal stemmerettigheder: 213.794.663
Yderligere information:
Søren Nielsen, koncernchef og adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
2025-06 Gennemførelse af kapitalnedsættelse.pdf
4.4.2025 10:05:55 CEST | Demant A/S |
Total number of voting rights and capital
Company announcement no 2025-06
4 April 2025
Completion of capital reduction in Demant A/S
As stated in company announcement no. 2025-04, it was decided at Demant A/S’ ordinary general meeting on 6 March 2025 to reduce the company’s share capital by nominally DKK 1,459,025.80 divided into 7,295,129 shares of DKK 0.20, corresponding to the company’s holding of treasury shares as at 4 February 2025 less shares to cover share-based retention programmes for senior leadership and the Executive Board.
The capital reduction was published via the electronic information system of the Danish Business Authority on 6 March 2025. The advertisement period expired without any objections being raised. Consequently, we have notified the Danish Business Authority of the capital reduction. After the capital reduction, the share capital of Demant A/S amounts to nominally DKK 42,758,932.60.
In accordance with section 32 of the Danish Capital Markets Act, we hereby state that the company’s total share capital and total number of voting rights amount to:
Share capital (nominal): DKK 42,758,932.60
Number of voting rights: 213.794.663
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
2025-06 Completion of capital reduction.pdf
